John Neylan, Chief Medical Officer of Keryx Biopharmaceuticals, Inc. (KERX) Just Sold Shares; Core Laboratories N V (CLB) Sentiment Is 1.07

Keryx Biopharmaceuticals Inc Chief Medical Officer John Neylan on the January 31, 2018 unloaded a total of 1,541 shares of the Pinksheet-listed company valued around $7,412 USD. This is exactly based on the average stock price value of $4.8 USD. He also sold 1,322 shares that are worth $6,504 USD in the last month. Currently, John Neylan owns 121,138 shares or 0.10% of the company’s market capitalization.

Core Laboratories N.V. provides reservoir description, production enhancement, and reservoir management services to the gas and oil industry in the United States, Canada, and internationally. The company has market cap of $5.05 billion. It operates through three divisions: Reservoir Description, Production Enhancement, and Reservoir Management. It has a 65.69 P/E ratio. The Reservoir Description segment comprises the characterization of petroleum reservoir rock, fluid, and gas samples.

The stock decreased 1.50% or $1.74 during the last trading session, reaching $114.3. About 746,117 shares traded or 41.53% up from the average. Core Laboratories N.V. (CLB) has declined 5.82% since February 1, 2017 and is downtrending. It has underperformed by 22.52% the S&P500.

Wcm Investment Management Ca holds 5.66% of its portfolio in Core Laboratories N.V. for 4.54 million shares. Wedgewood Partners Inc owns 1.13 million shares or 3.8% of their US portfolio. Moreover, Sustainable Growth Advisers Lp has 3.65% invested in the company for 2.71 million shares. The New York-based Riverpark Advisors Llc has invested 3.42% in the stock. Energy Opportunities Capital Management Llc, a Texas-based fund reported 48,563 shares.

Investors sentiment decreased to 1.5 in 2017 Q3. Its down 0.47, from 1.97 in 2017Q2. It worsened, as 12 investors sold Keryx Biopharmaceuticals, Inc. shares while 26 reduced holdings. 14 funds opened positions while 43 raised stakes. 75.60 million shares or 1.12% less from 76.46 million shares in 2017Q2 were reported. Timpani Cap Mngmt Ltd Liability Corporation invested in 192,756 shares or 0.5% of the stock. Aperio Llc stated it has 13,226 shares. California State Teachers Retirement System accumulated 143,144 shares or 0% of the stock. Moreover, Quantitative Invest Ltd Liability has 0.01% invested in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). Blackrock reported 5.99 million shares or 0% of all its holdings. Bankshares Of Montreal Can has invested 0% in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). Rhenman And Prns Asset Mngmt Ab invested 0.36% of its portfolio in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). Knoll Mgmt L P holds 1.21% of its portfolio in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) for 200,000 shares. California Pub Employees Retirement Sys stated it has 196,600 shares. Deutsche Bank Ag holds 0% of its portfolio in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) for 101,348 shares. 83,386 are owned by Perceptive Advsrs Lc. First Republic Invest Mgmt holds 0% of its portfolio in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) for 24,653 shares. Raymond James Fincl Serv Advsr Incorporated accumulated 17,525 shares or 0% of the stock. 120,870 were reported by Credit Suisse Ag. Lpl Limited Liability Company holds 47,602 shares or 0% of its portfolio.

Since October 5, 2017, it had 0 buys, and 11 insider sales for $134,733 activity. Adams Brian sold $3,532 worth of stock or 753 shares. Madison Greg sold $5,004 worth of stock. Another trade for 1,179 shares valued at $7,699 was made by Neylan John F. on Monday, October 23. Carberry Christine A. sold $44,064 worth of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) on Thursday, January 18. Holmes Scott A sold $15,569 worth of stock or 2,582 shares.

Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with renal disease in the United States. The company has market cap of $552.00 million. It markets its lead product Auryxia , an orally available, absorbable, iron medicine for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. It currently has negative earnings. The firm has licensing and collaboration agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan.

The stock decreased 1.91% or $0.09 during the last trading session, reaching $4.63. About 834,756 shares traded. Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) has risen 13.56% since February 1, 2017 and is uptrending. It has underperformed by 3.14% the S&P500.

Among 15 analysts covering Keryx Biopharmaceuticals (NASDAQ:KERX), 6 have Buy rating, 2 Sell and 7 Hold. Therefore 40% are positive. Keryx Biopharmaceuticals has $18 highest and $1.80 lowest target. $8.79’s average target is 89.85% above currents $4.63 stock price. Keryx Biopharmaceuticals had 36 analyst reports since July 23, 2015 according to SRatingsIntel. On Thursday, September 3 the stock rating was initiated by Citigroup with “Sell”. On Friday, July 8 the stock rating was maintained by Maxim Group with “Buy”. The company was maintained on Tuesday, August 2 by Ladenburg Thalmann. The company was maintained on Thursday, August 6 by Maxim Group. The firm earned “Market Perform” rating on Tuesday, August 2 by FBR Capital. The company was upgraded on Monday, October 5 by Morgan Stanley. On Tuesday, August 2 the stock rating was downgraded by Stifel Nicolaus to “Hold”. The stock of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) earned “Mkt Perform” rating by FBR Capital on Tuesday, August 11. The firm earned “Market Perform” rating on Thursday, July 23 by Cowen & Co. The rating was maintained by Maxim Group with “Buy” on Thursday, February 25.

Analysts await Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) to report earnings on March, 7. They expect $-0.19 EPS, up 40.63% or $0.13 from last year’s $-0.32 per share. After $-0.20 actual EPS reported by Keryx Biopharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -5.00% EPS growth.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: